Biotechnologies , Inc ., Atara Biotherapeutics , Inc ., Celgene Corporation , Cellular Biomedicine Group , GlaxoSmithKline plc , Immunocore Ltd ., Cell Medica , and Inovio Pharmaceuticals , Inc .
Table of Contents 1 . Analyst View 2 . Research Methodology 3 . Introduction 4 . Market Dynamics
4.1 Market Drivers 4.1.1 Increasing Number of Investments and Grants 4.1.2 Technological Advancements 4.1.3 Robust and Opportunistic Pipeline
Download sample Copy of This Report at : http :// www . radiantinsights . com / research / t- cell-immunotherapy-for-cancer-pipeline-analysis / request-sample
4.1.4 Collaboration Amongst Industry Players and Non-Industry Participants 4.1.5 Rising Research Related Activities 4.1.6 Venture Capitalist Funding
4.2 Challenges 4.2.1 Manufacturing and Regulatory Challenges 4.2.2 High Cost of Manufacturing Coupled With Demand for Scalability 4.2.3 Limited Validation of CAR-T Therapy Outside Of CD19 + Hematological Malignancies
4.3 Opportunities 4.3.1 Juno Therapeutics , Kite Pharma , Novartis Offering Great Opportunities 4.3.2 CAR-T Therapies Are Likely To Gain Momentum in Near Future
5 . Major Therapeutic Areas for T-Cell Therapies 5.1 Hematological Malignancies
Follow Us :